Research and Markets: Global Acute Lung Injury Pipeline Review - H2 2013

Business Wire


Research and Markets ( has announced the addition of the "Acute Lung Injury - Pipeline Review, H2 2013" report to their offering.

'Acute Lung Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury.


  • A snapshot of the global therapeutic scenario for Acute Lung Injury.
  • A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acute Lung Injury pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Companies Involved in Acute Lung Injury Therapeutics Development

  • GlaxoSmithKline plc
  • Quark Pharmaceuticals, Inc.
  • Discovery Laboratories, Inc.
  • Silence Therapeutics plc.
  • Altor BioScience Corporation
  • Mondobiotech Holding AG
  • Polyphor Ltd.
  • Implicit Bioscience Limited
  • KYORIN Pharmaceutical Co., Ltd.
  • Techpool Bio-Pharma Co., LTD.
  • Mayo Clinic
  • Faron Pharmaceuticals, Ltd.
  • APEPTICO Forschung und Entwicklung GmbH

Drug Profiles

  • POL-6014
  • dilmapimod
  • lucinactant
  • ALT-836
  • KRP-109
  • GSK-2586881
  • etanercept
  • Atu-111
  • interferon beta-1a
  • interferon beta-1a
  • aspirin
  • rosuvastatin calcium
  • Atu-134
  • PanCyte
  • AP-301
  • GSK-1995057
  • CT-2009
  • DasKloster-1000-04
  • DasKloster-014101
  • isoflurane
  • T-0901317
  • Drug Targeting Leptin
  • TP-405
  • Xib-1301
  • Mesenchymal Stem Cells
  • Drug Inhibiting IGF-1R
  • TAT-SNAP-23
  • rPAI-1
  • S-1226
  • S-1229

For more information visit

View Comments (0)